If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides; decalcified sections will not be accepted; must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section). Pathology review by a Nationwide Children's Laboratory Services pathologist will be performed on all tumor samples to verify tumor percentage.

All submitted specimens must contain minimum of ≥10% tumor. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen. 

All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.

Send all samples via overnight courier service. Send snap-frozen or OCT-embedded tissue buried in dry ice. Send fresh tissue and paraffin-embedded tissue at room temperature. Saturday deliveries are accepted; please check "Saturday Delivery" on shipment label for Saturday delivery. Please call (614) 722-5321 for any questions regarding this test.

This test includes FISH analyses performed on tumor specimens and identifies amplification of the MYCN (N-MYC) and MYC (C-MYC) oncogene loci. Presence or absence of MYCN and MYC amplification may be used to help determine molecular subgroup and risk classification for medulloblastoma and other tumors.

Medulloblastoma is the most common malignant brain tumor in children. Several biomarkers are used to determine the classification of medulloblastoma subtype, which affect treatment decisions. Identifying gene amplifications for MYCN and MYC oncogenes is used to help determine clinical subtype classification of medulloblastoma, provide prognostic information, and guide treatment.

Patients have variable risk (low, intermediate, or high) based on a variety of clinical and biological factors. These include age at diagnosis, extent of surgical resection, metastatic status, and histological features. Recently, molecular subgroups of medulloblastoma have been established based on gene expression signatures. These four subgroups have disparate mutational spectra, cytogenetic characteristics, and clinical phenotypes.

• The WNT molecular subgroup is documented for ~10% of medulloblastoma cases. This low-risk subgroup is characterized by somatic mutations in CTNNB1 as well as monosomy 6. Complete or partial monosomy for chromosome 6 is rare in other medulloblastoma subgroups. MYC and MYCN amplifications are almost never seen in this WNT subgroup.
• The SHH molecular subgroup is documented for ~25-30% of medulloblastoma cases. This group is considered as intermediate-risk and is characterized by genetic alterations in genes in the SHH signaling pathway including amplification of the MYCN locus.
• The Group 3 subgroup is documented for ~25-30% of medulloblastoma cases; this group is considered as high-risk. Almost all cases in this Group 3 subgroup have aberrant MYC expression (including MYC amplification occurring in about 10-17% of patients in this subgroup).
• The Group 4 subgroup is the largest subgroup, seen in ~40-50% of medulloblastoma cases, and is considered as intermediate-risk. As with the SHH subgroup, this subgroup can also present with amplification of the MYCN locus.

References: Foussel MF and Robinson GW (2013). Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med. 3:a014308; Archer TC et al (2017). Medulloblastoma: molecular classification-based personal therapeutics. Neurotherapeutics. 14:265-273; Sengupta S et al (2017). The evolution of medulloblastoma therapy to personalized medicine. F1000Res. 6:490

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides; decalcified sections will not be accepted; must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section). Pathology review by a Nationwide Children's Laboratory Services pathologist will be performed on all tumor samples to verify tumor percentage.

All submitted specimens must contain minimum of ≥10% tumor. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen. 

All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.

Send all samples via overnight courier service. Send snap-frozen or OCT-embedded tissue buried in dry ice. Send fresh tissue and paraffin-embedded tissue at room temperature. Saturday deliveries are accepted; please check "Saturday Delivery" on shipment label for Saturday delivery. Please call (614) 722-5321 for any questions regarding this test.

This test includes FISH analyses performed on tumor specimens and identifies amplification of the MYCN (N-MYC) and MYC (C-MYC) oncogene loci. Presence or absence of MYCN and MYC amplification may be used to help determine molecular subgroup and risk classification for medulloblastoma and other tumors.

Medulloblastoma is the most common malignant brain tumor in children. Several biomarkers are used to determine the classification of medulloblastoma subtype, which affect treatment decisions. Identifying gene amplifications for MYCN and MYC oncogenes is used to help determine clinical subtype classification of medulloblastoma, provide prognostic information, and guide treatment.

Patients have variable risk (low, intermediate, or high) based on a variety of clinical and biological factors. These include age at diagnosis, extent of surgical resection, metastatic status, and histological features. Recently, molecular subgroups of medulloblastoma have been established based on gene expression signatures. These four subgroups have disparate mutational spectra, cytogenetic characteristics, and clinical phenotypes.

• The WNT molecular subgroup is documented for ~10% of medulloblastoma cases. This low-risk subgroup is characterized by somatic mutations in CTNNB1 as well as monosomy 6. Complete or partial monosomy for chromosome 6 is rare in other medulloblastoma subgroups. MYC and MYCN amplifications are almost never seen in this WNT subgroup.
• The SHH molecular subgroup is documented for ~25-30% of medulloblastoma cases. This group is considered as intermediate-risk and is characterized by genetic alterations in genes in the SHH signaling pathway including amplification of the MYCN locus.
• The Group 3 subgroup is documented for ~25-30% of medulloblastoma cases; this group is considered as high-risk. Almost all cases in this Group 3 subgroup have aberrant MYC expression (including MYC amplification occurring in about 10-17% of patients in this subgroup).
• The Group 4 subgroup is the largest subgroup, seen in ~40-50% of medulloblastoma cases, and is considered as intermediate-risk. As with the SHH subgroup, this subgroup can also present with amplification of the MYCN locus.

References: Foussel MF and Robinson GW (2013). Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med. 3:a014308; Archer TC et al (2017). Medulloblastoma: molecular classification-based personal therapeutics. Neurotherapeutics. 14:265-273; Sengupta S et al (2017). The evolution of medulloblastoma therapy to personalized medicine. F1000Res. 6:490

This test includes FISH analyses performed on tumor specimens and identifies amplification of the MYCN (N-MYC) and MYC (C-MYC) oncogene loci. Presence or absence of MYCN and MYC amplification may be used to help determine molecular subgroup and risk classification for medulloblastoma and other tumors.

Medulloblastoma is the most common malignant brain tumor in children. Several biomarkers are used to determine the classification of medulloblastoma subtype, which affect treatment decisions. Identifying gene amplifications for MYCN and MYC oncogenes is used to help determine clinical subtype classification of medulloblastoma, provide prognostic information, and guide treatment.

Patients have variable risk (low, intermediate, or high) based on a variety of clinical and biological factors. These include age at diagnosis, extent of surgical resection, metastatic status, and histological features. Recently, molecular subgroups of medulloblastoma have been established based on gene expression signatures. These four subgroups have disparate mutational spectra, cytogenetic characteristics, and clinical phenotypes.

• The WNT molecular subgroup is documented for ~10% of medulloblastoma cases. This low-risk subgroup is characterized by somatic mutations in CTNNB1 as well as monosomy 6. Complete or partial monosomy for chromosome 6 is rare in other medulloblastoma subgroups. MYC and MYCN amplifications are almost never seen in this WNT subgroup.
• The SHH molecular subgroup is documented for ~25-30% of medulloblastoma cases. This group is considered as intermediate-risk and is characterized by genetic alterations in genes in the SHH signaling pathway including amplification of the MYCN locus.
• The Group 3 subgroup is documented for ~25-30% of medulloblastoma cases; this group is considered as high-risk. Almost all cases in this Group 3 subgroup have aberrant MYC expression (including MYC amplification occurring in about 10-17% of patients in this subgroup).
• The Group 4 subgroup is the largest subgroup, seen in ~40-50% of medulloblastoma cases, and is considered as intermediate-risk. As with the SHH subgroup, this subgroup can also present with amplification of the MYCN locus.

References: Foussel MF and Robinson GW (2013). Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med. 3:a014308; Archer TC et al (2017). Medulloblastoma: molecular classification-based personal therapeutics. Neurotherapeutics. 14:265-273; Sengupta S et al (2017). The evolution of medulloblastoma therapy to personalized medicine. F1000Res. 6:490

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides; decalcified sections will not be accepted; must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section). Pathology review by a Nationwide Children's Laboratory Services pathologist will be performed on all tumor samples to verify tumor percentage.

All submitted specimens must contain minimum of ≥10% tumor. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen. 

All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.

Send all samples via overnight courier service. Send snap-frozen or OCT-embedded tissue buried in dry ice. Send fresh tissue and paraffin-embedded tissue at room temperature. Saturday deliveries are accepted; please check "Saturday Delivery" on shipment label for Saturday delivery. Please call (614) 722-5321 for any questions regarding this test.

This test includes FISH analyses performed on tumor specimens and identifies amplification of the MYCN (N-MYC) and MYC (C-MYC) oncogene loci. Presence or absence of MYCN and MYC amplification may be used to help determine molecular subgroup and risk classification for medulloblastoma and other tumors.

Medulloblastoma is the most common malignant brain tumor in children. Several biomarkers are used to determine the classification of medulloblastoma subtype, which affect treatment decisions. Identifying gene amplifications for MYCN and MYC oncogenes is used to help determine clinical subtype classification of medulloblastoma, provide prognostic information, and guide treatment.

Patients have variable risk (low, intermediate, or high) based on a variety of clinical and biological factors. These include age at diagnosis, extent of surgical resection, metastatic status, and histological features. Recently, molecular subgroups of medulloblastoma have been established based on gene expression signatures. These four subgroups have disparate mutational spectra, cytogenetic characteristics, and clinical phenotypes.

• The WNT molecular subgroup is documented for ~10% of medulloblastoma cases. This low-risk subgroup is characterized by somatic mutations in CTNNB1 as well as monosomy 6. Complete or partial monosomy for chromosome 6 is rare in other medulloblastoma subgroups. MYC and MYCN amplifications are almost never seen in this WNT subgroup.
• The SHH molecular subgroup is documented for ~25-30% of medulloblastoma cases. This group is considered as intermediate-risk and is characterized by genetic alterations in genes in the SHH signaling pathway including amplification of the MYCN locus.
• The Group 3 subgroup is documented for ~25-30% of medulloblastoma cases; this group is considered as high-risk. Almost all cases in this Group 3 subgroup have aberrant MYC expression (including MYC amplification occurring in about 10-17% of patients in this subgroup).
• The Group 4 subgroup is the largest subgroup, seen in ~40-50% of medulloblastoma cases, and is considered as intermediate-risk. As with the SHH subgroup, this subgroup can also present with amplification of the MYCN locus.

References: Foussel MF and Robinson GW (2013). Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med. 3:a014308; Archer TC et al (2017). Medulloblastoma: molecular classification-based personal therapeutics. Neurotherapeutics. 14:265-273; Sengupta S et al (2017). The evolution of medulloblastoma therapy to personalized medicine. F1000Res. 6:490